Intrinsic Value

The intrinsic value of Novozymes A/S (NZM) under the Base Case is 6.86 EUR per share. Compared with the current market price of 59.5 EUR, the stock appears Overvalued by 88% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

NZM Intrinsic Value
€6.86
Overvaluation 88%
Intrinsic Value
Price €59.5
Alert me when NZM is below its intrinsic value
Today €5.49 · 90.8% below the current price

NZM is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to NZM

Fundamental Analysis

What Novozymes A/S Does

Chemicals Materials

Novozymes A/S, a beacon of innovation in biotechnology, operates at the intricate intersection of science and sustainability. Born from the storied roots of Novo Nordisk in 2000, this Danish company has carved out a niche in the enzyme and microbial sector. Novozymes’ core competency lies in its ability to harness the power of natural organisms, using them to drive forward industrial solutions that are not only efficient but also eco-friendly.

Headquarters
Denmark DK
Employees
6 184
IPO date
May 27, 1905
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Novozymes A/S

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one NZM stock?

The intrinsic value for Novozymes A/S (NZM) under the Base Case is 6.86 EUR.

Is NZM stock undervalued or overvalued?

Compared with the current market price of 59.5 EUR, the stock appears Overvalued by 88% .

Back to Top